AGEN Agenus Inc.

2.5
0  0%
Previous Close 2.5
Open 2.5
Price To Book -2.17
Market Cap 424,442,040
Shares 169,776,816
Volume 2,198,623
Short Ratio
Av. Daily Volume 2,387,628
Stock charts supplied by TradingView

NewsSee all news

  1. Agenus NextGen CTLA-4 Antibody (AGEN1181) Data to be Presented at ASCO

    LEXINGTON, Mass., May 14, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infections, announced today

  2. FDA Clears AgenTus IND for Allogeneic iNKT Cell Therapy

    LEXINGTON, Mass., May 13, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infectious diseases, announced

  3. Agenus First Quarter Results and Update

    LEXINGTON, Mass., May 7, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers provided a corporate update and

  4. Agenus to Report First Quarter 2020 Financial Results on May 7, 2020 and Host Conference Call and Webcast

    LEXINGTON, Mass., April 28, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, will release its first quarter

  5. Agenus Receives Fast Track Designation for Balstilimab in Advanced Cervical Cancer

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

BLA filing due 2020. Data February 20, 2020 noted 20.6% overall response rate (ORR), which included a complete response (CR) rate of 8.8% in second-line cervical cancer - Data February 20, 2020.
Balstilimab (anti-PD-1) and zalifrelimab (anti-CTLA-4)
Solid tumors
Phase 1/2 ongoing.
Zalifrelimab - AGEN1884 (anti-CTLA-4)
Solid cancers
Approval announced October 20, 2017.
Shingrix
Shingles
Phase 1 data from interim analysis noted ORR of 11.4% - February 20, 2020. BLA filing 2020.
Balstilimab (AGEN2034) anti-PD-1
Cervical cancer
Phase 1 data presented at Investor Day February 20, 2020.
AGEN1181 - 2nd gen CTLA
Advanced cancer

Latest News

  1. Agenus NextGen CTLA-4 Antibody (AGEN1181) Data to be Presented at ASCO

    LEXINGTON, Mass., May 14, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infections, announced today

  2. FDA Clears AgenTus IND for Allogeneic iNKT Cell Therapy

    LEXINGTON, Mass., May 13, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infectious diseases, announced

  3. Agenus First Quarter Results and Update

    LEXINGTON, Mass., May 7, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers provided a corporate update and

  4. Agenus to Report First Quarter 2020 Financial Results on May 7, 2020 and Host Conference Call and Webcast

    LEXINGTON, Mass., April 28, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, will release its first quarter

  5. Agenus Receives Fast Track Designation for Balstilimab in Advanced Cervical Cancer

  6. Agenus Receives Fast Track Designation for Balstilimab & Zalifrelimab in Advanced Cervical Cancer

    LEXINGTON, Mass., March 12, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced that the U.S.

  7. Agenus Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

    LEXINGTON, Mass., March 12, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers provided a corporate update and

  8. First QS-21 Royalty Payment Due to Agenus is Triggered

    LEXINGTON, Mass., March 10, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, announced the triggering of a

  9. Agenus Announces Positive Interim Data from Balstilimab and Zalifrelimab Clinical Trials in Second-Line Cervical Cancer

    LEXINGTON, Mass., Feb. 20, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced new clinical

  10. Agenus Announces Investor Day on February 20, 2020

    LEXINGTON, Mass., Feb. 6, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced it will hold an

  11. Agenus Announces the Appointment of Dr. Jennifer Buell to the position of President and COO

    LEXINGTON, Mass., Jan. 9, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, is pleased to announce the appointment

  12. Agenus Commences Phase 1 trial with AGEN1223

    LEXINGTON, Mass., Jan. 8, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, announced the dosing of the first

  13. Agenus Commences Combination Trial of its Next-Gen CTLA-4 with its PD-1 Antibody

    LEXINGTON, Mass., Dec. 19, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, today announced

  14. Agenus to Host R&D Day November 15, 2019

    LEXINGTON, Mass., Nov. 12, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced that it

  15. UroGen Pharma Announces Exclusive License Agreement with Agenus Inc to Advance Treatment of Urinary Tract Cancers

    UroGen to Develop and Commercialize Zalifrelimab (AGEN1884, anti-CTLA-4 antibody) with UGN-201 for High-Grade Non-Muscle Invasive Bladder Cancer UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical

  16. Agenus receives $10M from UroGen Pharma for rights to Zalifrelimab (CTLA-4) for intravesical treatment of urinary tract cancers

    LEXINGTON, Mass., Nov. 11, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today

  17. Agenus Provides Corporate Update with Third Quarter 2019 Financial Results

    LEXINGTON, Mass., Nov. 4, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1, and cancer vaccines provided a

  18. Agenus to Report Third Quarter 2019 Financial Results on November 4, 2019 and Host Conference Call and Webcast

    LEXINGTON, Mass., Oct. 31, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its third quarter 2019 financial

  19. Agenus to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019

    LEXINGTON, Mass., Sept. 30, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today

  20. VBI Vaccines Announces Phase 2a Clinical Evaluation of VBI-1901 Cancer Vaccine Candidate in Combination with GSK's AS01B Adjuvant System in Recurrent Glioblastoma Patients

    - VBI is the first biopharma company to collaborate with GSK to assess AS01B adjuvant system as part of a therapeutic cancer vaccine candidate - Combination will be tested in additional study arm in Part B of VBI's